

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Airdoc Technology Co., Ltd.
北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2251)

**DISCLOSEABLE AND MAJOR TRANSACTIONS IN RELATION TO
SUBSCRIPTION OF STRUCTURED DEPOSITS
AND
SUPPLEMENTAL ANNOUNCEMENT TO INTERIM RESULTS
ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024**

**DISCLOSEABLE AND MAJOR TRANSACTIONS IN RELATION TO
SUBSCRIPTION OF STRUCTURED DEPOSITS**

The Board announces that, between January 14, 2022 and July 4, 2024, the Group subscribed to the CMB Structure Deposits and the XIB Structured Deposits for cash and treasury management purpose. As of the date of this announcement, the Group has redeemed all the aforesaid Structured Deposits.

Principal Terms of the Structured Deposits

The principal terms of the Structured Deposits are set out as follows:

	CMB Structured Deposits	XIB Structured Deposits
Name:	Gold-Linked Series Bearish Two-tier 24-day Structured Deposit (點金系列看跌兩層區間24天結構性存款)	Structured Deposit (Type A of Three-Intervals Pegged Exchange Rate) (結構性存款(掛鈎匯率三層區間A款))
Subscribing entity:	Company, Beijing Airdoc and Shanghai Airdoc	Beijing Intelligent Technology

	CMB Structured Deposits	XIB Structured Deposits
Deposit interest:	The deposit interest is linked to the RMB-denominated gold benchmark price, and ranged from 1.65% to 3.0% per annum	The deposit interest is pegged to the EUR/USD exchange rate, and ranged from 0.80% to 3.20% per annum
Term of product:	Ranging from 15 days to 3 months	Ranging from 19 days to 29 days
Type of product:	Principal-protected with floating interest rate, allowing flexible redemption without any penalty	
Nature of product:	Low-risk, high-liquidity and low-volatility	
Right of early termination or redemption:	In practice and as confirmed by CMB and XIB, early redemption or termination will not result in a penalty, but will only lead to the forfeiture of accrued interest up to the date of early redemption or termination, similar to the early termination or redemption of time deposits with commercial banks	

Subscriptions of CMB Structured Deposits

Between January 14, 2022 to July 4, 2024, the Company, Beijing Airdoc and Shanghai Airdoc subscribed to the CMB Structured Deposits on a rotational basis for a total of 40 times.

The following table sets forth the movements of each Subscription of the CMB Structured Deposits:

No.	Subscription date	Redemption date	Subscribing entity	Outstanding balance before the subscription (RMB)	Subscription amount (RMB)	Outstanding balance after the Subscription (RMB)
1.	January 14, 2022	January 28, 2022	Shanghai Airdoc	—	50,000,000	50,000,000
2.	January 21, 2022	March 22, 2022	Company	50,000,000	81,000,000	131,000,000
3.	January 21, 2022	March 22, 2022	Company	131,000,000	19,000,000	150,000,000
4.	February 7, 2022	February 28, 2022	Beijing Airdoc	100,000,000	8,000,000	108,000,000
5.	February 14, 2022	February 28, 2022	Shanghai Airdoc	108,000,000	50,000,000	158,000,000
6.	March 1, 2022	March 31, 2022	Beijing Airdoc	100,000,000	8,000,000	108,000,000
7.	March 8, 2022	March 28, 2022	Shanghai Airdoc	108,000,000	50,000,000	158,000,000
8.	April 11, 2022	April 29, 2022	Company	—	100,000,000	100,000,000
9.	April 11, 2022	April 29, 2022	Company	100,000,000	100,000,000	200,000,000
10.	May 5, 2022	May 31, 2022	Company	—	200,000,000	200,000,000
11.	June 2, 2022	June 27, 2022	Company	—	400,000,000	400,000,000

No.	Subscription date	Redemption date	Subscribing entity	Outstanding balance before the subscription (RMB)	Subscription amount (RMB)	Outstanding balance after the Subscription (RMB)
12.	July 14, 2022	September 28, 2022	Company	—	100,000,000	100,000,000
13.	July 29, 2022	September 29, 2022	Company	100,000,000	200,000,000	300,000,000
14.	September 7, 2022	September 28, 2022	Company	300,000,000	200,000,000	500,000,000
15.	October 28, 2022	December 28, 2022	Company	—	300,000,000	300,000,000
16.	December 5, 2022	December 28, 2022	Company	300,000,000	150,000,000	450,000,000
17.	January 18, 2023	March 28, 2023	Company	—	170,000,000	170,000,000
18.	January 19, 2023	February 24, 2023	Company	170,000,000	250,000,000	420,000,000
19.	March 3, 2023	April 18, 2023	Company	170,000,000	200,000,000	370,000,000
20.	April 6, 2023	May 8, 2023	Company	200,000,000	179,000,000	379,000,000
21.	April 24, 2023	June 26, 2023	Company	179,000,000	150,000,000	329,000,000
22.	May 11, 2023	May 31, 2023	Company	150,000,000	179,600,000	329,600,000
23.	June 14, 2023	June 30, 2023	Company	150,000,000	179,000,000	329,000,000
24.	July 3, 2023	July 31, 2023	Company	—	150,000,000	150,000,000
25.	August 1, 2023	October 7, 2023	Company	—	180,000,000	180,000,000
26.	September 6, 2023	November 6, 2023	Company	180,000,000	150,000,000	330,000,000
27.	October 18, 2023	December 29, 2023	Company	150,000,000	100,000,000	250,000,000
28.	November 9, 2023	December 29, 2023	Company	100,000,000	150,000,000	250,000,000
29.	November 9, 2023	December 29, 2023	Company	250,000,000	50,000,000	300,000,000
30.	January 25, 2024	April 26, 2024	Company	—	180,000,000	180,000,000
31.	February 6, 2024	April 7, 2024	Company	180,000,000	50,000,000	230,000,000
32.	February 9, 2024	April 9, 2024	Company	230,000,000	50,000,000	280,000,000
33.	February 28, 2024	March 28, 2024	Company	280,000,000	50,000,000	330,000,000
34.	March 18, 2024	April 19, 2024	Shanghai Airdoc	330,000,000	30,000,000	360,000,000
35.	April 2, 2024	April 23, 2024	Shanghai Airdoc	310,000,000	50,000,000	360,000,000
36.	April 3, 2024	June 3, 2024	Company	360,000,000	50,000,000	410,000,000
37.	April 3, 2024	June 3, 2024	Company	410,000,000	50,000,000	460,000,000
38.	May 6, 2024	May 30, 2024	Shanghai Airdoc	100,000,000	50,000,000	150,000,000
39.	May 6, 2024	August 6, 2024	Company	150,000,000	100,000,000	250,000,000
40.	May 13, 2024	July 15, 2024	Company	250,000,000	40,000,000	290,000,000

As of the date of this announcement, the Company has redeemed all outstanding CMB Structured Deposits.

Subscriptions of XIB Structured Deposits

Between August 3, 2023 to July 4, 2024, Beijing Intelligent Technology subscribed to the XIB Structured Deposits on a rotational basis for a total of 9 times.

The following table sets forth the movements of each Subscription of the XIB Structured Deposits:

No.	Subscription date	Redemption date	Subscribing entity	Outstanding balance before the Subscription (RMB)	Subscription amount (RMB)	Outstanding balance after the Subscription (RMB)
1.	August 3, 2023	August 31, 2023	Beijing Intelligent Technology	—	100,000,000	100,000,000
2.	October 13, 2023	October 31, 2023	Beijing Intelligent Technology	—	98,000,000	98,000,000
3.	November 6, 2023	November 30, 2023	Beijing Intelligent Technology	—	100,000,000	100,000,000
4.	December 5, 2023	December 29, 2023	Beijing Intelligent Technology	—	100,000,000	100,000,000
5.	January 5, 2024	January 31, 2024	Beijing Intelligent Technology	—	100,000,000	100,000,000
6.	February 5, 2024	February 29, 2024	Beijing Intelligent Technology	—	100,000,000	100,000,000
7.	March 6, 2024	March 29, 2024	Beijing Intelligent Technology	—	101,000,000	101,000,000
8.	June 5, 2024	June 28, 2024	Beijing Intelligent Technology	—	100,000,000	100,000,000
9.	July 4, 2024	July 31, 2024	Beijing Intelligent Technology	—	100,000,000	100,000,000

As of the date of this announcement, the Company has redeemed all outstanding XIB Structured Deposits.

Reasons for and Benefits of the Subscriptions

The Structured Deposits subscribed to by the Group were principal-protected, allowed flexible redemption without any penalties, and featured low risk, high liquidity, and low volatility. The Group conducted the Subscriptions as it considers these Structured Deposits provided more favorable yields than the time or demand deposits generally offered by commercial banks or licensed financial institutions, while ensuring the Group's cash and treasury management flexibility.

The Company consistently conducted cash and treasury management for funds not immediately required for business operations, with the objective of optimizing returns on idle cash while maintaining adequate liquidity. The Company considers that subscribing Structured Deposits with better yields is in line with its cash and treasury management policy. The Subscriptions were made for treasury management purpose to maximize return on the cash generated from its business operations and the IPO Proceeds that were not immediately required for the designated purposes, while ensuring principal protection and high liquidity. Furthermore, the Group has implemented appropriate internal control procedures designed to ensure that the Subscriptions would not affect the sufficiency of working capital of the Group or hinder the operation of the Group's businesses. Each Subscription was closely monitored and executed in strict compliance with the Group's cash and treasury management policy.

Having considered the above, the Directors, including the independent non-executive Directors, are of the view that the terms of the Structured Deposits are fair and reasonable and on normal commercial terms, and the Subscriptions are in the interests of the Company and its Shareholders as a whole and do not constitute a change in the use of the IPO Proceeds.

Information on the Parties Involved

The Company, Beijing Airdoc, Shanghai Airdoc and Beijing Intelligent Technology

The Company is focused on leveraging AI technology to provide comprehensive solutions for early detection, diagnosis and health risk assessment of chronic fundus and ophthalmic diseases, while also offering eye health management services such as myopia prevention and visual training.

Each of Beijing Airdoc, Shanghai Airdoc and Beijing Intelligent Technology is a limited liability company established in the PRC and a subsidiary of the Company, principally engaged in the sale of hardware devices and provision of AI-based software solutions.

CMB and XIB

CMB is a PRC licensed commercial bank and a joint stock company incorporated in the PRC, the shares of which are listed on the Shanghai Stock Exchange (stock code: 600036) and the Stock Exchange (stock code: 03968). CMB is principally engaged in retail finance and wholesale finance and the controlling shareholder of its largest shareholder is China Merchants Group Ltd.

XIB is a PRC licensed commercial bank principally engaged in banking services, whose head office is in Xiamen, the PRC. According to the publicly available information, XIB does not have any controlling shareholder (within the meaning of the Listing Rules). Its largest shareholder is Fujian Futou Investment Limited Liability Company (福建省福投投資有限責任公司) (holding 11.82% equity interest of XIB), which is wholly owned by Fujian Investment and Development Group Limited Liability Company (福建省投資開發集團有限責任公司) and the actual controller of which is the State-owned Assets Supervision and Administration Commission of the People's Government of Fujian Province.

As of the date of this announcement and to the best of the Directors' knowledge, information and belief having made all reasonable enquiries, CMB, XIB and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Listing Rules).

Listing Rules Implications

CMB Structured Deposits

As each of the CMB Structured Deposits was subscribed with the same bank and was of similar nature, the CMB Structured Deposits would, in each case, during the relevant period be aggregated and treated as if there were one transaction with CMB for the purpose of calculating the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of 39 out of these 40 Subscriptions of CMB Structured Deposits on a standalone basis exceeded 5% but was less than 25%, each of these 39 Subscriptions of CMB Structured Deposits on a standalone basis constituted a disclosable transaction of the Company and was subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules.

On certain occasions when the Group had not fully redeemed its existing CMB Structured Deposits before making a new Subscription of the CMB Structured Deposits, the highest applicable percentage ratio in respect of 14 out of these 40 Subscriptions of CMB Structured Deposits, after aggregation, exceeded 25% but was less than 100%. Therefore, each of these Subscriptions of the CMB Structured Deposits, upon aggregation, constituted a major transaction of the Company and was subject to the reporting, announcement and shareholders' approval requirements under Chapter 14 of the Listing Rules.

XIB Structured Deposits

As each of the XIB Structured Deposits was subscribed with the same bank and was of similar nature, the XIB Structured Deposits would, in each case, during the relevant period be aggregated and treated as if there were one transaction with XIB for the purpose of calculating the relevant percentage ratios pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of each Subscription of the XIB Structured Deposits on a standalone basis exceeded 5% but was less than 25%, each Subscription of the XIB Structured Deposits constituted a disclosable transaction of the Company and was subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules. None of the Subscriptions of XIB Structured Deposits, upon aggregation, constituted a major transaction of the Company under Chapter 14 of the Listing Rules.

SUPPLEMENTAL ANNOUNCEMENT TO INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

Reference is made to the Interim Results Announcement. The Board would like to supplement the following additional information regarding the use of the IPO Proceeds.

Use of the IPO Proceeds

As disclosed in the Interim Results Announcement, the Company's financial assets at fair value through profit or loss amounted to RMB445.8 million as of June 30, 2024, primarily due to subscription of certain wealth management products as a supplemental means to improve utilization of its idle cash on a short-term basis. Among these wealth management products, the Company subscribed to the note offered by Ideal Venture LP (the "Note") in the principal amount of US\$9 million in June 2024. The Note was principal-protected and allowed for early redemption without any penalties. As none of the applicable percentage ratios with respect to the subscription of the Note was above 5%, the subscription of the Note did not constitute a disclosable transaction under Chapter 14 of the Listing Rules.

As disclosed in the Prospectus, to the extent that the IPO Proceeds are not immediately applied to the designated purposes and to the extent permitted by the relevant laws and regulations, so long as it is deemed to be in the best interests of the Company, the Company may hold such funds in short-term deposits with licensed banks in Hong Kong. Taking into account that (i) the Note was low-risk, principal-protected and could be redeemed on demand; (ii) the Company's finance staff genuinely but mistakenly viewed the nature of the Note as essentially akin to bank deposits and viewed the subscription of the Note using Idle IPO Proceeds as an effective way to manage the Idle IPO Proceeds for achieving slightly more favorable returns while ensuring principal protection and maintaining high liquidity; and (iii) the subscription of the Note would not interfere with the Company's use of the IPO Proceeds as set out in the Prospectus, the Company's staff therefore placed a portion of the Idle IPO Proceeds into the subscription of the Note.

As of the date of this announcement, the Company has fully redeemed the Note and has received the principal amount of US\$9 million, together with the interests accrued up to the date of redemption. The Company will utilize the IPO Proceeds in accordance with the use of the IPO Proceeds as disclosed in the announcement of the Company dated August 28, 2024 and the circular of the Company dated September 27, 2024, which was approved by the Shareholders in the extraordinary general meeting on October 18, 2024.

REMEDIAL MEASURES

The Company deeply regrets the aforementioned non-compliance with the Listing Rules. To prevent similar incidents in the future, the Company has implemented the following remedial measures:

Internal Control Review

To improve the internal control of the Group, the Company engaged the internal control consultant team of a top-tier consulting firm (the “**IC Consultant**”) as its independent internal control consultant to conduct a thorough review of the internal control system, policies and procedures in respect of the Group’s investment, cash and treasury management and IPO Proceeds management activities, and the IC Consultant has provided the Company with corresponding rectification and improvement recommendations in order to address potential loopholes in the Group’s investment, cash and treasury management and IPO Proceeds management procedures and internal control system, and prevent similar incident in the future (the “**Internal Control Review**”).

Details of the Internal Control Review are summarized as follows:

Scope of the Internal Control Review

The scope of the Internal Control Review mainly covers the following aspects:

- (i) understanding the management framework, organizational structure and division of responsibilities in respect of the Group’s activities related to investment, cash and treasury management and IPO Proceeds management;
- (ii) reviewing the relevant internal control policies and procedures;
- (iii) understanding work performed by management personnel and finance staff and their understanding of the relevant internal control procedures and provisions of the Listing Rules; reviewing documents evidencing relevant transactions;
- (iv) conducting gap analysis on the current status of the Group’s internal control procedures and the corresponding information disclosure mechanism with reference to the leading practices of companies listed on the Stock Exchange, identifying potential risks and area for improvement, and providing rectification and improvement recommendations; and
- (v) discussing identified issues with the Company’s management team and assisting the Company in developing a remediation action plan.

Procedures performed by the IC Consultant

When conducting the Internal Control Review, the IC Consultant performed the following procedures:

- (i) conducting interviews with relevant management personnel, including Directors, senior management and employees responsible for investment, cash and treasury management and IPO Proceeds management to identify key control points and key risks;
- (ii) examining records and documentation, including relevant transaction documents and correspondences related to the Group's activities regarding investments, cash and treasury management and IPO Proceeds management, performing walk-through and control tests; and
- (iii) benchmarking the Group's practices against the relevant provisions of the Listing Rules, specifically Chapter 14 (Notifiable Transactions) and Chapter 14A (Connected Transactions) of the Listing Rules, as well as the leading practices of companies listed on the Stock Exchange.

Limitations of the Internal Control Review

The Internal Control Review was subject to the following limitations:

- (i) the Internal Control Review does not constitute any audit, review, or attestation of the Company's financial statements under auditing standards, nor does it constitute or provide any legal or tax opinion or advice. The IC Consultant did not perform procedures to detect fraud or illegal activities; and
- (ii) the IC Consultant did not perform procedures to identify, resolve, or correct errors or defects in the Company's computer system or any related equipment or components, whether such errors or defects were caused by erroneous or ambiguous data input, storage, interpretation, processing, or reporting. The IC Consultant is not responsible for any defects or problems arising from data processing within the system or operations related thereto.

Key Findings, Recommendations and Company's Responses

Key Findings	Rectification and Improvement Recommendations	Company's response and remediation status
<p>1. The Group's policies and procedures for investment management were not updated in a timely manner, which may lead to operational staff lacking clear guidance when carrying out certain procedures.</p> <p>2. Non-compliance with disclosure requirements for the subscription of Structured Deposits.</p> <p>3. Finance staff did not report certain transactions to the Board through the established procedures due to misclassification of the nature of the Company's investments.</p>	<p>It is recommended the Company to, among others:</p> <ul style="list-style-type: none"> (i) update and refine its internal reporting and approval procedure for investment management to include more detailed approval requirements at different stage of the process; (ii) clarify and specify the scope and definition of investments, financial products and/or wealth management products in the relevant policies by enumerating common types of treasury management transactions; (iii) circulate a detailed guideline relating to notifiable and connected transactions under the Listing Rules and the use and management of IPO Proceeds, and establish a detailed checklist for identifying transactions that need to be disclosed and regularly review such checklist on a monthly or quarterly basis; (iv) set up an approval procedure to require the finance staff to consult legal department when assessing and categorizing financial products and/or wealth management products, and to further require that the subscription to any such products will be jointly approved by finance, internal audit and legal departments and the CEO; and (v) set up a procedure to require relevant staff to consult external auditors, legal advisors, and other professional parties as and when appropriate to ensure compliance with the disclosure requirements under the Listing Rules. 	<p>The Group has accepted and fully implemented the aforesaid recommendations.</p>

Key Findings	Rectification and Improvement Recommendations	Company's response and remediation status
4. The Company needs to provide more training to relevant personnel regarding the classification of the nature of the Company's investments and the relevant disclosure requirements under the Listing Rules.	It is recommended the Company to provide periodic training to its management, finance staff and other related staff every one to two months with a view to enhancing their understanding of the revised internal control procedures, the classification of the nature of the Company's investments and the relevant disclosure requirements under the Listing Rules.	The Group has accepted and fully implemented the aforesaid recommendation.
5. Pre-investment due diligence and post-investment management and documentation processes need to be further strengthened.	<p>It is recommended the Company to, among others:</p> <ul style="list-style-type: none"> <li data-bbox="608 661 1027 768">(i) before making investments, conduct due diligence, feasibility analysis and comprehensive research; <li data-bbox="608 810 1027 949">(ii) after making investments, monitor ongoing investments through periodic review on a bi-monthly or quarterly basis, and report project updates; and <li data-bbox="608 991 1027 1066">(iii) improve documentation and record keeping regarding investment activities. 	The Group has accepted and fully implemented the aforesaid recommendations.
6. Guidelines for the management of IPO Proceeds need to be further enhanced.	<p>It is recommended the Company to, among others:</p> <ul style="list-style-type: none"> <li data-bbox="608 1189 1027 1598">(i) refine the guidelines for the management of IPO Proceeds by clearly defining the standards and scope for permissible cash and treasury management of Idle IPO Proceeds and distinguishing the use of Idle IPO Proceeds from general cash and treasury management activities in terms of internal approval processes, to ensure appropriate internal review and approval for the use, change in use and management of the IPO Proceeds; and <li data-bbox="608 1630 1027 1915">(ii) conduct quarterly review of the use of IPO Proceeds, including providing explanation for discrepancies between planned schedule of use and actual schedule of use of the IPO Proceeds, and properly documenting and disclosing cash and treasury management activities for the Idle IPO Proceeds. 	The Group has accepted and fully implemented the aforesaid recommendations.

Compliance Adviser

The Company has engaged Alliance Capital Partners Limited, who is qualified under Chapter 3A of the Listing Rules, as its compliance adviser to provide additional assistance to the Company, the Board, and the Company’s finance department for Listing Rules compliance until the date on which the Company complies with Rule 13.46 of the Listing Rules in respect of its financial results for the financial year ending December 31, 2025.

DEFINITIONS

“Beijing Airdoc”	Beijing Airdoc Health Technology Co., Ltd. (北京鷹瞳健康科技有限公司), a company established in the PRC with limited liability on August 30, 2018 and a subsidiary of our Company
“Beijing Intelligent Technology”	Beijing Airdoc Intelligent Technology Co. Ltd. (北京鷹瞳智能科技有限公司), a company established in the PRC with limited liability on October 14, 2021 and a subsidiary of our Company
“Board”	the board of Directors
“Company”	Beijing Airdoc Technology Co., Ltd. (北京鷹瞳科技發展股份有限公司), a joint stock company incorporated in the PRC with limited liability on September 9, 2015 and the H Shares of which were listed on the Stock Exchange on November 5, 2021
“CMB”	China Merchants Bank Co., Ltd. (招商銀行股份有限公司), a commercial bank and a joint stock company incorporated in the PRC with limited liability, the shares of which are listed on the Shanghai Stock Exchange (stock code: 600036) and the Stock Exchange (stock code: 03968)
“CMB Structured Deposits”	the structured deposits offered by CMB and subscribed to by the Group
“Director(s)”	director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“Idle IPO Proceeds”	the portion of the IPO Proceeds that are not immediately required for the designated purposes in the relevant year
“Interim Results Announcement”	the interim results announcement of the Company for the six months ended June 30, 2024

“IPO Proceeds”	the proceeds obtained by the Company from the Global Offering (as defined in the Prospectus)
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China, excluding Hong Kong, the Macau Special Administrative Region and Taiwan for the purpose of this announcement
“Prospectus”	the prospectus of the Company dated October 26, 2021 in respect of the Company’s initial public offering in Hong Kong
“RMB”	Renminbi Yuan, the lawful currency of China
“Shares”	shares in the share capital of the Company, with a nominal value of RMB1.00 each, comprising unlisted shares and H Shares
“Shanghai Airdoc”	Shanghai Airdoc Medical Technology Co., Ltd. (上海鷹瞳醫療科技有限公司), a company established in the PRC with limited liability on July 26, 2017 and a subsidiary of our Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscription(s)”	subscription(s) of the Structured Deposits
“Structured Deposits”	CMB Structured Deposits and XIB Structured Deposits
“XIB”	Xiamen International Bank Co., Ltd. (廈門國際銀行股份有限公司), a commercial bank and a joint stock company incorporated in the PRC with limited liability
“XIB Structured Deposits”	the structured deposits offered by XIB and subscribed to by the Group
“%”	per cent

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, December 20, 2024

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Ms. WANG Lin, Dr. HE Chao and Mr. QIN Yong as executive Directors; and Dr. WU Yangfeng and Dr. HUANG Yanlin as independent non-executive Directors.